1. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms

   • Kerstin Röhss
   • Tore Lind
   • Clive Wilder-Smith

   Pharmacodynamics 02 September 2004 Pages: 531 - 539

   

2. Electrocardiogram and cardiovascular changes in thioridazine and chlorpromazine poisoning

   • E. M. Strachan
   • C. A. Kelly
   • D. N. Bateman

   Pharmacodynamics 15 September 2004 Pages: 541 - 545

   

3. Fatal intoxication cases: cytochrome P ₄₅₀ 2D6 and 2C19 genotype distributions

   • A. L. Zackrisson
   • P. Holmgren
   • B. Lindblom

   Pharmacogenetics 02 September 2004 Pages: 547 - 552

4. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine

   • Kazushi Sawamura
   • Yutaro Suzuki
   • Toshiyuki Someya

   Pharmacogenetics 03 September 2004 Pages: 553 - 557

   

5. Effects of growth hormone deficiency and rhGH replacement therapy on the 6β-hydroxycortisol/free cortisol ratio, a marker of CYP3A activity, in growth hormone-deficient children

   • Blanca Sinués
   • Esteban Mayayo
   • Angel Ferrández-Longás

   Pharmacogenetics 07 September 2004 Pages: 559 - 564

6. Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro

   • Einosuke Tanaka
   • Yui Takano
   • Katsuya Honda

   Pharmacokinetics and Disposition 04 September 2004 Pages: 565 - 568

   

7. Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women

   • Ricardo de Carvalho Cavalli
   • Vera Lúcia Lanchote
   • Sérgio Pereira da Cunha

   Pharmacokinetics and Disposition 07 September 2004 Pages: 569 - 574

   

8. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes

   • Kyoung-Ah Kim
   • Jaegul Chung
   • Ji-Young Park

   Pharmacokinetics and Disposition 08 September 2004 Pages: 575 - 581

   

9. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions

   • Stanislav Micuda
   • Lucie Mundlova
   • Jirina Martinkova

   Pharmacokinetics and Disposition 16 September 2004 Pages: 583 - 589

   

10. Diclofenac systemic exposure is not increased when topical diclofenac is applied to ultraviolet-induced erythema

    • J. -L. Magnette
    • J. -L. Kienzler
    • A. Knops

    Pharmacokinetics and Disposition 29 September 2004 Pages: 591 - 594

11. Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany

    • Verena Bergk
    • Christiane Gasse
    • Walter E. Haefeli

    Pharmacoepidemiology and Prescription 04 September 2004 Pages: 595 - 602

    

12. Protease inhibitors and diltiazem increase tacrolimus blood concentration in a patient with renal transplantation: a case report

    • Gaëlle Hardy
    • Françoise Stanke-Labesque
    • Germain Bessard

    Short Communication 15 September 2004 Pages: 603 - 605

    

13. A new opportunity for thalidomide? Further randomised controlled trial are necessary

    • Federico Marchetti
    • Marzia Lazzerini
    • Alessandro Ventura

    Letter to the Editors 03 September 2004 Pages: 607 - 608